Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
China’s NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.
Summary:. Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well…
Drs. Junko Tanizaki, Seshiru Nakazawa, and Motoko Tachihara, members of the IASLC DEI Taskforce, emphasize the importance of participating in the IASLC Global Survey on…
In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.
An abstract is unavailable.
We have been profiling people who illustrate the culture and spirit of Fred Hutch with the Heart of the Hutch series. This edition focuses on…
A thoracic expert explains what lymph nodes are and how they’re involved in lung cancer diagnosis and treatment.
A new initiative launched in 20 states, including Florida and Georgia, aims to gain an understanding of cancer disparities and other health conditions among black…
The International Association for the Study of Lung Cancer (IASLC) is proud to announce that it is now accepting applications for groups of qualified IASLC…
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.